ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Nephrol Dial Transplant. 2009 Dec;24(12):3557-66. doi: 10.1093/ndt/gfp519. Epub 2009 Oct 9.
BACKGROUND: Recent studies have indicated a stabilization in the incidence rates of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in a number of European countries. The aim of this study was to provide an update on the incidence, prevalence and outcomes of RRT in Europe over the past decade. METHODS: Nineteen European national or regional renal registries with registry data from 1997 to 2006 participated in the study. Incidence and prevalence trends were analysed with Poisson and Joinpoint regression. Cox regression methods were used to examine patient survival. RESULTS: The total adjusted incidence rate of RRT for ESRD increased from 109.9 per million population (pmp) in 1997 to 119.7 pmp in 2000, i.e. an average annual percentage change (AAPC) of 2.9% (95% CI 2.1-3.8%). Thereafter, the incidence increased at a much lower rate to 125.4 pmp in 2006 [AAPC 0.6% (95% CI 0.3-0.8%)]. This change in the trend of the incidence of RRT was largely due to a stabilization in the incidence rates of RRT for females aged 65-74 years, males aged 75-84 years and patients receiving RRT for ESRD due to hypertension/renal vascular disease. The overall adjusted prevalence in Europe continued to increase linearly at 2.7% per year. Between the periods 1997-2001 and 2002-2006, the risk of death decreased for all treatment modalities, with the most substantial improvement in patients starting peritoneal dialysis [19% (95% CI 15-22%)] and in patients receiving a kidney transplant [17% (95% CI 11-23%)]. CONCLUSION: This European study shows that the annual rise of the overall incidence rate of RRT for ESRD has diminished and that in several age groups the incidence rates have now stabilized. The survival of dialysis patients and kidney transplant recipients has continued to improve.
背景:最近的研究表明,在一些欧洲国家,终末期肾病(ESRD)的肾脏替代治疗(RRT)发病率已趋于稳定。本研究旨在提供过去十年欧洲 RRT 的发病率、患病率和结局的最新情况。
方法:19 个欧洲国家或地区的肾脏登记处参与了这项研究,这些登记处提供了 1997 年至 2006 年的数据。使用泊松和 Joinpoint 回归分析发病率和患病率趋势。使用 Cox 回归方法检查患者的生存率。
结果:调整后的 ESRD 患者 RRT 总发病率从 1997 年的每百万人口 109.9 例(pmp)增加到 2000 年的 119.7 pmp,即平均年变化百分比(AAPC)为 2.9%(95%可信区间 2.1-3.8%)。此后,发病率的增加速度要低得多,到 2006 年达到 125.4 pmp[AAPC 为 0.6%(95%可信区间 0.3-0.8%)]。RRT 发病率趋势的这种变化主要归因于 65-74 岁女性、75-84 岁男性以及因高血压/肾血管疾病接受 RRT 的 ESRD 患者的 RRT 发病率的稳定。欧洲的总体调整后患病率继续以每年 2.7%的速度线性增长。在 1997-2001 年和 2002-2006 年期间,所有治疗方式的死亡风险均降低,腹膜透析患者(19%(95%可信区间 15-22%))和接受肾移植患者(17%(95%可信区间 11-23%))的改善最为显著。
结论:这项欧洲研究表明,总体 ESRD 患者 RRT 发病率的年增长率已有所下降,并且在一些年龄组中,发病率已经趋于稳定。透析患者和肾移植受者的生存率持续提高。
Nephrol Dial Transplant. 2009-10-9
J Nephrol. 2009
Nephrol Dial Transplant. 2009-3
Nephrol Dial Transplant. 2010-3-5
Nephrol Dial Transplant. 2004-12
Am J Kidney Dis. 2011-3
Clin Kidney J. 2023-11-13
Nephrol Dial Transplant. 2023-5-31
Clin Kidney J. 2020-12-26
Anesth Pain Med. 2020-10-20
Nephrol Dial Transplant. 2021-4-26